Αρχική World News Efficacy of Talquetamab Plus Teclistamab in Patients with Extramedullary Myeloma World News Efficacy of Talquetamab Plus Teclistamab in Patients with Extramedullary Myeloma Από Ogkologos - 10 Δεκεμβρίου, 2025 659 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the phase II cohort of the RedirecTT-1 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Generic Dasatinib 10 Φεβρουαρίου, 2022 Study Tackles Key Questions about Liver Transplants for People with Liver... 24 Αυγούστου, 2022 Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with... 17 Φεβρουαρίου, 2026 Tipifarnib Demonstrates Encouraging Efficacy in Patients with Recurrent and/or Metastatic HNSCC... 21 Απριλίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Dwayne Johnson Sends Special “Moana” Message To 3-Yr-Old Battling Cancer. Best Friends and Owners of a Specialty Cheese Shop Battle Breast... Limited Efficacy of Nivolumab plus Ipilimumab in Adenoid Cystic Carcinomas, but... ESMO Sarcoma and Rare Cancers Congress 2024